| Aralkylamine N-acetyltransferase | |
| Ec Number: | 2.3.1.87 |
| Cas Number: | 92941-56-5 |
| Go Code: | 0004059 |
| Aralkylamine N-acetyltransferase | |
| Hgncid: | 19 |
| Symbol: | AANAT |
| Entrezgene: | 15 |
| Omim: | 600950 |
| Refseq: | NM_001088 |
| Uniprot: | Q16613 |
| Ecnumber: | 2.3.1.87 |
| Chromosome: | 17 |
| Arm: | q |
| Band: | 25 |
Aralkylamine N-acetyltransferase (AANAT), also known as arylalkylamine N-acetyltransferase or serotonin N-acetyltransferase (SNAT), is an enzyme that is involved in the day/night rhythmic production of melatonin, by modification of serotonin. It is in humans encoded by the ~2.5 kb AANAT gene[1] containing four exons, located on chromosome 17q25.[2] The gene is translated into a 23 kDa large enzyme. It is well conserved through evolution and the human form of the protein is 80 percent identical to sheep and rat AANAT. It is an acetyl-CoA-dependent enzyme of the GCN5-related family of N-acetyltransferases (GNATs). It may contribute to multifactorial genetic diseases such as altered behavior in sleep/wake cycle[1] and research is on-going with the aim of developing drugs that regulate AANAT function.
The systematic name of this enzyme class is acetyl-CoA:2-arylethylamine N-acetyltransferase. Other names in common use include:
The officially accepted name is aralkylamine N-acetyltransferase.[3]
The AANAT mRNA transcript is mainly expressed in the central nervous system (CNS). It is detectable at low levels in several brain regions including the pituitary gland as well as in the retina. It is most highly abundant in the pineal gland which is the site of melatonin synthesis. Brain and pituitary AANAT may be involved in the modulation of serotonin-dependent aspects of human behavior and pituitary function.[2]
In the pinealocyte cells of the pineal gland, aralkylamine N-acetyltransferase is involved in the conversion of serotonin to melatonin. It is the penultimate enzyme in the melatonin synthesis controlling the night/day rhythm in melatonin production in the vertebrate pineal gland. Melatonin is essential for seasonal reproduction, modulates the function of the circadian clock in the suprachiasmatic nucleus, and influences activity and sleep. Due to its important role in circadian rhythm, AANAT is subjected to extensive regulation that is responsive to light exposure (see Regulation). It may contribute to multifactorial genetic diseases such as altered behavior in sleep/wake cycle and mood disorders.[1]
The primary chemical reaction that is catalyzed by aralkylamine N-acetyltransferase uses two substrates, acetyl-CoA and serotonin. AANAT catalyzes the transfer of the acetyl group of Acetyl-CoA to the primary amine of serotonin, thereby producing CoA and N-acetylserotonin. In humans, other endogenous substrates of the enzyme include specific trace amine neuromodulators, namely phenethylamine, tyramine, and tryptamine, in turn forming N-acetylphenethylamine, N-acetyltyramine, and N-acetyltryptamine.[4]
In the biosynthesis of melatonin, N-acetylserotonin is further methylated by another enzyme, N-acetylserotonin O-methyltransferase (ASMT) to generate melatonin. The N-acetyltransferase reaction has been suggested to be the rate-determining step, and thus Serotonin N-acetyltransferase has emerged as a target for inhibitor design (see below).[5]
AANAT obeys an ordered ternary-complex mechanism. The substrates bind sequentially (ordered) with acetyl-CoA binding to the free enzyme followed by the binding of serotonin to form the ternary complex. After the transfer of the acetyl group has occurred, the products are orderly released with N-acetyl-serotonin first and CoA last.[6]
Arylkylamine N-acetyltransferase is a monomeric polypeptide with a length of 207 amino acid residues, and with a molecular weight of 23,344 daltons. The secondary structure consists of alpha helices and beta sheets. It is 28 percent helical (10 helices; 60 residues) and 23 percent beta sheet (9 strands; 48 residues). This family shares four conserved sequence motifs designated A-D. Motif B serves as the location of the serotonin binding slot. The structure was determined by X-ray diffraction.
Several structures have been solved for this class of enzymes, with PDB accession codes,[7],[8],[9] and //.
Aralkylamine N-acetyltransferase has also been crystallized in complex with 14-3-3ζ from the 14-3-3 protein family, with the PDB accession code .[10]
Aralkylamine N-acetyltransferase belongs to the GCN5-related N-acetyltransferase (GNAT) superfamily which consists 10,000 acetyltransferases, named so because of their sequence homology to a class of eukaryotic transcription factors, therein the yeast GCN5. Other well-studied members of the superfamily are glucosamine-6-phosphate N-acetyltransferase and histone acetyltransferases.
All members of this superfamily has a structurally conserved fold consisting of an N-terminal strand followed by two helices, three antiparallel β-strands, followed by a ‘‘signature’’ central helix, a fifth β-strand, a fourth α-helix and a final β-strand. These elements are nearly universally conserved in spite of poor pairwise identity in sequence alignments.[11]
Regulation of AANAT varies between species. In some, AANAT levels oscillate dramatically between light and dark periods, and thus control melatonin synthesis. In others, rhythm is regulated primarily on the protein level.[12] One example is in rodents, where AANAT mRNA levels increase more than 100-fold in dark periods. In other species, cyclic AMP plays an important part in inhibition of proteolytic degradation of AANAT, elevating protein levels at night. Experiments using human AANAT expressed in a 1E7 cell line show an ~8-fold increase in enzyme activity upon exposure to forskolin.[13]
Dynamic degradation of AANAT mRNA has proven essential to the circadian action of the enzyme. The 3’UTR sequences have importance with regards to the rhythmic degradation of AANAT mRNA in some species. In rodents, various hnRNPs maintain dynamic degradation of AANAT mRNA. In other species, such as ungulates and primates, the stable AANAT mRNAs with a shorter 3’UTR is suspected not to be under control of the hnRNPs that bind and direct degradation of AANAT mRNA in rodents.[14]
Exposure to light induces signals to travel from retinal cells, ultimately causing a drop in norepinephrine stimulation of the pineal gland. This, in turn, leads to a signaling cascade, resulting in Protein Kinase A phosphorylation of two key Ser and Thr residues of serotonin N-acetyltransferase. Phosphorylation of these residues causes changes in catalytic activity through recruitment and interaction with 14-3-3 proteins, specifically 14-3-3ζ.[15]
Another protein which interacts and regulates AANAT activity is protein kinase C. Protein kinase C acts, like protein kinase A, on threonine and serine residues, enhancing the stability and enzymatic activity of AANAT.[16]
Inhibition of the acetyl-CoA-binding to the catalytic site through the formation and cleavage of intramolecular disulfide bonds has been suggested to be a mechanism of regulation. Formation of a disulfide bond between two cystein residues within the protein closes the hydrophobic funnel of the catalytic site, and thus acts as an on/off switch for catalytic activity. It is not yet certain if this mechanism is present in in vivo cells through the regulation of intracellular redox conditions, but it is suggested that glutathione (GSH) could be an in vivo regulator of the formation and cleavage of these disulfide bonds.[17]
Inhibitors of AANAT may eventually lead to development of a drug that would be useful in circadian biology research and in the treatment of sleep and mood disorders. Synthetic inhibitors of the enzyme have been discovered.[18] [19] [20] However, no AANAT inhibitor with potent in vivo activity has been reported.[21] Up to now, five classes of AANAT inhibitors have been described in the literature. Below are the five classes:
Since it was reported that melatonin is a competitive inhibitor of AANAT, this neurotransmitter seems to exert an autoregulatory control on its own biosynthesis. Thus, loose structural analogues of the indolamine hormone were evaluated on AANAT, and moderate inhibitors were discovered.[22]
Peptide combinatorial libraries of tri-, tetra-, and pentapeptides with various amino acid compositions were screened as potential sources of inhibitors, to see if it serves as either pure or mixed competitive inhibitor for the hAANAT enzyme. Molecular modeling and structure-activity relationship studies made it possible to pinpoint the amino acid residue of the pentapeptide inhibitor S 34461 that interacts with the cosubstrate-binding site.[23]
It is suggested that AANAT catalyzes the transfer of an acetyl group from acetyl-CoA to serotonin, with the involvement of an intermediate ternary complex, to produce N-acetylserotonin. Based on this mechanism, it might be expected that a bisubstrate analog inhibitor, derived from the tethering of indole and CoASH parts, could potentially mimic the ternary complex and exert strong inhibition of AANAT.[24] The first bisubstrate analog (1), which links tryptamine and CoA via an acetyl bridge, was synthesized by Khalil and Cole, and shown to be a very potent and specific AANAT inhibitor.[25]
AANAT has shown that it also has a secondary alkyltransferase activity as well as acetyltransferase activity.[26] N-Haloacetyltryptamines were developed and serve as substrates of AANAT alkyltransferase and are also potent (low micromolar) in vitro inhibitors against AANAT acetyltransferase activity. AANAT catalyzes reaction between N-bromoacetyltryptamine (BAT) and reduced CoA, resulting a tight-binding bisubstrate analog inhibitor.[26] [27] The first synthesized cell-permeable inhibitor of AANAT N-bromoacetyltryptamine was studied further on melatonin secretion from rat and pig pineal glands.[28] New N-halogenoacetyl derivatives leading to a strong in situ inhibition of AANAT. The concept behind the mechanism of action of these precursors was studied by following the biosynthesis of the inhibitor from tritiated-BAT in a living cell.
The first druglike and selective inhibitors of AANAT has been identified. Lawrence M. Szewczuk et al. have virtually screened more than a million compounds by 3D high-throughput docking into the active site of X-ray structure for AANAT, and then tested 241 compounds as inhibitors. One compound class which containing a rhodanine scaffold has shown low micromolar competitive inhibition against acetyl-CoA and proved to be effective in blocking melatonin production in pineal cells.
The recent study about inhibitor of AANAT has described the discovery of a new class of nonpeptidic AANAT inhibitors based on a 2,2′-bithienyl scaffold.[21]